Altasciences

AltasciencesNorth American CRO/CDMO with extensive capabilities from drug discovery to non-clinical and clinical development. We have research facilities in the US and Canada, and we provide contract non-clinical studies such as pharmacology, PK/PD, toxicology, safety pharmacology, and bioanalysis.

Features of Altasciences' nonclinical contract research services

Comprehensive evaluation from small molecules to biopharmaceuticals

At Altasciences,Non-clinical evaluation targeting both small and large molecule drugsIt supports lead compound optimization, dose setting, PK/PD, pharmacology, safety pharmacology, and toxicity studies, allowing tests to be combined according to the development stage. We support a wide range of animal species, including mice, rats, guinea pigs, rabbits, pigs, miniature pigs, dogs, and non-human primates. We also support multiple administration routes such as oral, intravenous, infusion, ocular, dermal, and implant, designing studies tailored to the characteristics of the candidate compound.

GLP-compliant toxicity studies and safety pharmacology

GLP safety evaluation anticipating IND applications and similar processesAnother feature is the ability to conduct single and acute toxicity, dose range finding, repeated dose, chronic toxicity, and carcinogenicity studies, as well as safety pharmacology targeting the CNS, cardiovascular, and respiratory systems. Evaluations can be performed using both rodents and non-rodents. Programs can be tailored to the development stage, ranging from early toxicity evaluations to pivotal toxicology. The official website states that toxicity tests are conducted in compliance with GLP to support submissions to regulatory agencies in North America, Europe, Japan, and elsewhere.

Consistent support from bioanalysis to SEND

We can coordinate the peripheral operations required for non-clinical studies in-house.This is also a strength of Altasciences. By combining bioanalysis, PK/TK data analysis, immunohistochemistry, clinical pathology, necropsy pathology, and more, study results can be evaluated from multiple perspectives. We also support SEND, which formats nonclinical study data for regulatory submissions. Furthermore, we provide scientific and regulatory advice, protocol development, project management, and report generation, offering comprehensive support from candidate selection through nonclinical development for first-in-human trials.

An example of a disease model owned by Altasciences

At Altasciences,multiple therapeutic areas such as CNS, immunology, inflammation, and metabolismWe conduct non-clinical pharmacology and safety evaluations. In particular, in the CNS field, we also support research utilizing various models, including primates. We have established a system that enables the transition to PK/PD and safety evaluations while confirming the pharmacological effects of candidate compounds.

Altasciences non-clinical study cases

Conducting IND-enabling studies for a GLP-1 receptor agonist

AltasciencesPre-IND study in dogs using a small-molecule GLP-1 receptor agonistWe have published a case study focusing on how pharmacological appetite suppression and weight loss complicate the interpretation of toxicity evaluations, and we adopted a study design that distinguishes between pharmacological effects and safety findings. By combining toxicity evaluations and pharmacokinetic data, we assisted in acquiring the non-clinical data required for an IND application.

Altasciences Company Profile